



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 9448/PJO

*(Use as many sheets as necessary)*

**Complete if Known**

Application Number	10/803,482
Filing Date	March 18, 2004
First Named Inventor	Monia et al.
Art Unit	1652
Examiner Name	unassigned McGarry
Attorney Docket Number	BIOL0003US

Sheet	1	of	4
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>o</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
SM ✓	AL	EP-1308459-A2	05-07-2003	Isogai et al.		
✓	AM	WO-00/78961	12-28-2000	Ferrara et al.		
✓	AN	WO-01/68848	09-20-2001	Baker et al.		
✓	AO	WO-01/77389	10-18-2001	Seilhamer et al		
SM	AP	WO-02/08260	01-31-2002	Perou et al.		

**Examiner  
Signature**

/Sean McGarry/

Date Considered

10/11/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/803,482
				Filing Date	March 18, 2004
				First Named Inventor	Monia et al.
				Group Art Unit	1652
				Examiner Name	unassigned
Sheet	2	of	4	Attorney Docket Number	BIOL0003US

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SM	AR	BUHMAN et al., "DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis", <i>J. Biol. Chem.</i> <b>July 12, 2002</b> 277:25474-25479	
SM	AS	CASES et al., "Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis", <i>Proc. Natl. Acad. Sci. USA</i> <b>October 27, 1998</b> 95:13018-13023	
SM	AT	CASES et al., "Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members", <i>J. Biol. Chem.</i> <b>October 19, 2001</b> 276:38870-38876	
SM	AU	CHEN et al., "Increased insulin and leptin sensitivity in mice lacking acyl CoA: diacylglycerol acyltransferase 1", <i>J. Clin. Invest.</i> <b>April 2002</b> 109:1049-1055	
SM	AV	CHEN et al., "Leptin modulates the effects of acyl CoA: diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands", <i>J. Clin. Invest.</i> <b>January 2002</b> 109:175-181	
SM	AW	CHENG et al., "Human acyl-CoA: diacylglycerol acyltransferase is a tetrameric protein", <i>Biochem. J.</i> <b>November 1, 2001</b> 359:707-714	
SM	AX	FARESE et al., "Triglyceride synthesis: insights from the cloning of diacylglycerol acyltransferase", <i>Curr. Opin. Lipidol.</i> <b>June 2000</b> 11:229-234	

Examiner Signature	/Sean McGarry/	Date Considered	10/11/2006
--------------------	----------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/803,482
				Filing Date	March 18, 2004
				First Named Inventor	Monia et al.
				Group Art Unit	1652
				Examiner Name	unassigned
Sheet	3	of	4	Attorney Docket Number	BIOL0003US

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
SM	AY	LARDIZABAL et al., "DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from Mortierella ramanniana with diacylglycerol acyltransferase activity", <i>J. Biol. Chem.</i> <b>October 19, 2001</b> 276:38862-38869	
SM	AZ	LUDWIG et al., "DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women", <i>Clin. Genet.</i> <b>July 2002</b> 62:68-73	
SM	BR	MEEGALLA et al., "Concerted elevation of acyl-coenzyme A: diacylglycerol acyltransferase (DGAT) activity through independent stimulation of mRNA expression of DGAT1 and DGAT2 by carbohydrate and insulin", <i>Biochem. Biophys. Res. Commun.</i> <b>November 1, 2002</b> 298:317-323	
SM	BS	OELKERS et al., "Characterization of two human genes encoded acyl coenzyme A: cholesterol acyltransferase-related enzymes", <i>J. Biol. Chem.</i> <b>October 9, 1998</b> 273:26765-26771	
SM	BT	SMITH et al., "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT", <i>Nat. Genet.</i> <b>May 2000</b> 25:87-90	
SM	BU	TABATA et al., "Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus", <i>Phytochemistry</i> <b>October 1997</b> 46:683-687	
SM	BV	TOMODA et al., "Roselipins, inhibitors of diacylglycerol acyltransferase, produced by Gliocladium roseum KF-1040", <i>J. Antibiot. (Tokyo)</i> <b>August 1999</b> 52:689-694	

Examiner Signature	/Sean McGarry/	Date Considered	10/11/2006
--------------------	----------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

[illegible]

\* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

***If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.***



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

Sheet

2

of

2

**Complete if Known**

<b>Application Number</b>	<b>10/803.482</b>
---------------------------	-------------------

<b>Filing Date</b>	<b>03/18/2004</b>
--------------------	-------------------

<b>First Named Inventor</b>	<b>Brett P. Monia</b>
-----------------------------	-----------------------

<b>Art Unit</b>	<b>1635</b>
-----------------	-------------

<b>Examiner Name</b>	<b>Sean McGarry</b>
----------------------	---------------------

<b>Attorney Docket Number</b>	<b>BIOL0003US</b>
-------------------------------	-------------------

## NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner  
Signature**

/Sean McGarry/

Date \_\_\_\_\_

**Considered**

10/11/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**

PTO-1449 REPRODUCED  <b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  February 21, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 4042.3009 US1 (formerly BIOL0003US)		APPLICATION NO. 10/803,482	
	FIRST NAMED APPLICANT Brett P. Monia			
	FILING DATE March 18, 2004		CONFIRMATION NO. 6288	GROUP 1652

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
SM	AA2	US 2004/0107459 A1	03-JUNE-2004	Lardizabal <i>et al.</i>
V	AB2	US 2004/0076977 A1	22-APR-2004	Georges <i>et al.</i>
	AC2	US 2004/0078836 A1	22-APR-2004	Farese <i>et al.</i>
SM	AD2	US 2004/0185559 A1	23-SEP-2004	Monia <i>et al.</i>

U.S. CO-PENDING APPLICATIONS				
EXAM- INER INI- TIAL	REF. NO.	APPLICATION SERIAL NUMBER	FILING DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	BA			
	BB			

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	MM-DD-YYYY PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	CA					
	CB					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	DA	
	DB	

EXAMINER	/Sean McGarry/	DATE CONSIDERED	10/11/2006
----------	----------------	-----------------	------------